The Comprehensive Guide to Plecanatide
The global pharmaceutical landscape is continually evolving, with peptide-based drugs representing a rapidly growing segment of the industry.
Among them, Plecanatide has emerged as a significant treatment for chronic gastrointestinal conditions.
First approved by the U.S. Food and Drug Administration (FDA) in 2017, Plecanatide offers a targeted management of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
For API importers, medicine manufacturers, and compounding pharmacies, understanding the intricacies of Plecanatide is not just about adding another product to a portfolio; it is the right move in the fierce market competition.
This comprehensive guide dives deep into every aspect of Plecanatide—from its fundamental pharmacology to advanced sourcing strategies—providing the technical knowledge needed to navigate this specialized market effectively.
What is Plecanatide?
Plecanatide API is a synthetic, 16-amino acid peptide analog of the human gastrointestinal hormone uroguanylin.
It was developed by Synergy Pharmaceuticals (originally by Callisto Pharmaceuticals) as an oral therapeutic for gastrointestinal disorders.
With a molecular weight of approximately 1.682 kDa, Plecanatide is structurally characterized by its cyclic formation, stabilized by disulfide bridges between specific cysteine residues (Cys4-Cys12 and Cys7-Cys15).
This molecular design is crucial for its stability and function. The key structural distinction between Plecanatide and natural uroguanylin is a single amino acid substitution that enhances its stability and increases its binding affinity to the guanylate cyclase-C (GC-C) receptor by approximately eightfold compared to the native hormone.
This enhanced binding ability translates to improved efficacy, making Plecanatide a potent agonist of the GC-C receptor, which is predominantly expressed on the luminal surface of intestinal epithelial cells.
Unlike systemic medications, Plecanatide only acts locally within the gastrointestinal tract.
A critical feature for pharmaceutical professionals to note is its minimal systemic absorption after oral administration.
Studies using sensitive detection methods, such as LC-MS, have shown that the oral bioavailability of similar peptides (such as linaclotide) is less than 0.11%.
This targeted action minimizes off-target effects and reduces the risk of systemic adverse events, making it a highly safe therapeutic agent against constipation.
What is Plecanatide Used For?
Plecanatide is indicated for the treatment of specific chronic gastrointestinal conditions in adult patients.
Its approved uses include:
Chronic Idiopathic Constipation (CIC) is the primary indication for which Plecanatide received initial FDA approval. CIC is characterized by persistent, complex, infrequent, or seemingly incomplete bowel movements without an identifiable organic cause. It affects a significant portion of the population, with estimates suggesting a prevalence of around 15% in the United States (approximately 33 million people) and 4-6% in China, with rates increasing with age. Plecanatide offers a therapeutic option for patients who have not responded adequately to conventional laxatives.
Irritable Bowel Syndrome with Constipation (IBS-C): Following its initial approval for CIC, Synergy Pharmaceuticals planned to submit a supplemental New Drug Application (sNDA) to the FDA for the treatment of IBS-C in March 2017. IBS-C is a functional bowel disorder characterized by abdominal pain associated with altered bowel habits, predominantly constipation. The drug’s dual action of increasing fluid secretion and reducing gut pain sensitivity makes it well-suited for this condition.
The significant patient population for these conditions—over 100 million people globally suffer from CIC and IBS-C—underscores the substantial market opportunity for Plecanatide.
How Does Plecanatide Work? (Mechanism of Action)
The therapeutic action of Plecanatide is a sophisticated example of harnessing human physiology for therapeutic benefit.
Its mechanism of action can be broken down into a sequence of molecular and cellular events:
Receptor Binding: Upon oral ingestion and transit to the small intestine, Plecanatide binds to and activates the guanylate cyclase-C (GC-C) receptor, located on the apical (luminal) surface of intestinal epithelial cells. Plecanatide is designed to be a potent analog of the endogenous hormone uroguanylin, which is a natural ligand for this receptor.
Intracellular Second Messenger Production: The activation of the GC-C receptor stimulates the intracellular domain of the receptor to convert guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). This leads to a significant increase in intracellular cGMP concentration.
Ion Channel Activation: The elevated cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel. The activated CFTR channel secretes chloride and bicarbonate ions into the intestinal lumen.
Fluid Secretion and Motility: The ionic gradient established by CFTR activation draws water passively into the intestinal lumen through osmosis. This increase in intestinal fluid volume softens the stool and promotes intestinal motility, thereby stimulating bowel movements. Additionally, increased cGMP has been shown to reduce the activity of pain-sensing nerves in the gut, which may contribute to its benefits in reducing abdominal pain in conditions like IBS-C.
The following table summarizes this mechanism and compares it to other drugs in its class:
*Table 1: Mechanism of Action Comparison for GC-C Agonists and Related Drugs*
| Drug Name | Class | Molecular Target | Primary Effect | Result |
|---|---|---|---|---|
| Plecanatide (Trulance) | GC-C Agonist | Guanylate Cyclase-C (GC-C) Receptor | ↑ Intracellular cGMP → CFTR activation → Cl⁻/HCO₃⁻ secretion | Increased intestinal fluid, accelerated transit, reduced pain |
| Linaclotide (Linzess) | GC-C Agonist | Guanylate Cyclase-C (GC-C) Receptor | ↑ Intracellular cGMP → CFTR activation → Cl⁻/HCO₃⁻ secretion | Increased intestinal fluid, accelerated transit, reduced pain |
| Lubiprostone (Amitiza) | Chloride Channel Activator | CIC-2 Chloride Channel | Direct activation → Cl⁻ secretion → fluid secretion | Increased intestinal fluid and transit |
What Are the Brand Names of Plecanatide?
The primary and most recognized brand name for Plecanatide is Trulance®. This is the trademark under which Synergy Pharmaceuticals introduced the drug to the U.S. market following FDA approval on January 19, 2017.
In addition to the brand name, Plecanatide is known by its generic name and various chemical and research names, which are particularly important for API suppliers and manufacturers dealing with regulatory documentation and Certificates of Analysis (CoA). These include:
Plecanatide: The official generic name.
Plecanatide acetate: The acetate salt form, commonly used in pharmaceutical formulations (CAS Number: 1075732-84-1).
The free base form has the CAS number 467-426-54-6.
When sourcing the Active Pharmaceutical Ingredient (API), it is crucial to specify the correct salt form and confirm the associated CAS number to ensure material consistency and regulatory compliance. The drug product is formulated as an oral tablet containing 3 mg of Plecanatide.
Does Plecanatide Cause Weight Gain?
A critical consideration for both prescribers and patients is the potential for pharmaceuticals to cause weight changes.
Based on available clinical data and its mechanism of action, Plecanatide is not associated with weight gain.
Several key factors can explain this:
Localized Action: As previously emphasized, Plecanatide acts locally within the gastrointestinal tract and exhibits negligible systemic absorption. It does not interact with systemic metabolic pathways or central nervous system receptors (like those for neurotransmitters or hormones) that are typically implicated in drug-induced weight gain.
Mechanism of Action: Drugs that cause weight gain often do so by increasing appetite, causing fluid retention, or altering metabolic rates. Plecanatide’s action is confined to promoting fluid secretion in the gut. It does not stimulate appetite or affect energy metabolism.
Clinical Evidence: The clinical trial program supporting the FDA approval of Plecanatide for CIC did not report weight gain as an adverse event. The most common side effect was diarrhea, which is consistent with its pharmacologic activity.
In contrast, medications that affect the central nervous system, such as certain antipsychotics (e.g., risperidone) or antidepressants, are known to cause weight gain by interfering with neurotransmitters that regulate appetite and satiety.
Plecanatide’s targeted, peripheral mechanism sets it apart from such drugs.
For manufacturers and pharmacies, this is a valuable safety point that can be highlighted in educational materials for healthcare providers.
How Effective is Plecanatide?
The efficacy of Plecanatide was firmly established in a robust clinical development program comprising multiple Phase III randomized, double-masked, placebo-controlled trials involving thousands of patients with CIC.
The trials used a standardized regulatory endpoint known as “responder analysis.” A responder was defined as a patient who experienced:
At least three Complete Spontaneous Bowel Movements (CSBMs) per week.
An increase of at least one CSBM from their baseline frequency.
This response had to be sustained for at least 9 out of the 12 treatment weeks, including 3 of the final 4 weeks.
The results were statistically significant and clinically relevant:
In two pivotal trials, the responder rates for the 3 mg Plecanatide group were 21%, compared to 10% and 13% in the respective placebo groups. It represents a substantial relative improvement.
The drug demonstrated a rapid onset of action, with patients experiencing an increase of approximately 1.1 more CSBMs per week compared to the placebo, an effect that was sustained throughout the 12-week treatment period.
Importantly, upon discontinuation of the drug after the 12-week treatment, bowel habits returned to baseline levels within two weeks, confirming that the effect was directly attributable to the drug.
Data also indicated that Plecanatide helped normalize stool consistency to a healthier state, as measured by the Bristol Stool Form Scale.
From an industry perspective, its efficacy profile is comparable to that of linaclotide (Linzess).
Still, it may offer a potentially improved tolerability profile regarding the incidence of severe diarrhea, a key differentiator discussed later.
How Long Does It Take for Plecanatide to Work?
Patients and prescribers often prioritize the speed of therapeutic effect. Clinical data indicate that Plecanatide has a relatively rapid onset of action.
Improvements in bowel movement frequency and consistency can often be observed within the first week of treatment.
The clinical trials demonstrated a clear separation from placebo on the primary endpoint (CSBMs) early in the treatment course, with the effect sustained throughout the 12-week study period.
This rapid onset is pharmacologically logical. The drug does not need to accumulate in the bloodstream to be effective.
Instead, it acts topically on the intestinal lining upon passage through the gastrointestinal tract.
For manufacturers, this rapid onset is a key marketing advantage that can be communicated to highlight the drug’s benefits compared to slower-acting bulk-forming or osmotic laxatives.
Plecanatide Precautions and Drug Interactions
Understanding the safety profile and potential interactions is crucial for risk management.
Precautions and Contraindications:
Pediatric Patients: Plecanatide is contraindicated in pediatric patients under 6 years of age due to the risk of severe dehydration. Its safety and effectiveness in patients 6 to 18 years old have not been established; therefore, its use in this population should be avoided.
Mechanical GI Obstruction: It is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction because increased intestinal secretion could exacerbate the condition.
Diarrhea: Patients should be advised that diarrhea is a common side effect. They should discontinue use if severe diarrhea occurs and maintain adequate hydration.
Drug Interactions:
A significant advantage of Plecanatide is its low potential for systemic drug-drug interactions.
Because it is minimally absorbed and acts locally in the gut, it is unlikely to interfere with the pharmacokinetics of systemically acting drugs that are metabolized by cytochrome P450 enzymes or transported by P-glycoprotein.
So it is a desirable option for patients with CIC or IBS-C who are on multiple medications for other chronic conditions, simplifying the treatment regimen and reducing concerns about polypharmacy.
What Are the Side Effects of Plecanatide?
The side effect profile of Plecanatide is directly related to its pharmacologic activity.
The most common adverse reaction is diarrhea.
Incidence and Management: In clinical trials, the incidence of diarrhea in Plecanatide-treated patients was less than 6%, which was higher than placebo but notably lower than the 16% reported for linaclotide. This lower rate of diarrhea, particularly severe diarrhea requiring discontinuation, is a potential competitive advantage. The diarrhea is typically mild to moderate. Management involves patient education, dose timing (e.g., taking the medication with food), and ensuring adequate hydration. Severe diarrhea may require temporary discontinuation.
Other Side Effects: Other reported adverse effects include abdominal pain, flatulence, and feeling bloated, which are common to many therapies for functional gastrointestinal disorders. Serious adverse events were rare (approximately 1% in trials) and similar to those in the placebo group.
Discontinuation Rate: The rate of patients stopping treatment due to adverse events in clinical trials was approximately 5% for Plecanatide, compared to 8% for linaclotide, suggesting better overall tolerability.
What Are the Differences Between Linaclotide and Plecanatide?
Linaclotide API and Plecanatide API are both GC-C agonists used for similar gastrointestinal indications, but they have significant differences:
Structural Differences:
Linaclotide is a 14-amino acid peptide
Plecanatide is a 16-amino acid peptide
Plecanatide is structurally more similar to native uroguanylin
Mechanistic Nuances:
Plecanatide demonstrates pH-dependent binding, with greater activity in the acidic environment of the duodenum and proximal small intestine
Linaclotide’s activity is less pH-dependent
Clinical Differences:
Both drugs show similar efficacy for CIC and IBS-C
Some studies suggest a potentially slightly lower rate of diarrhea with Plecanatide, though direct comparative trials are not available
Dosing differs somewhat between the two medications
Commercial Considerations:
Linaclotide has a longer market presence and broader global approval
Plecanatide may offer alternative options for patients who cannot tolerate Linaclotide
For API purchasers and formulators, both compounds offer opportunities in the growing gastrointestinal drug market, though they share similar technical challenges in peptide synthesis, characterization, and formulation.
How Much Does Plecanatide API Cost?
As an API or finished product supplier, pricing is a dynamic and market-specific factor.
Providing exact current costs is not feasible as they vary significantly by country, purchaser (e.g., wholesaler, pharmacy, hospital), and insurance coverage.
However, it is known that as a branded prescription drug in the U.S., Trulance® has a significant list price.
The manufacturer, Synergy, initially projected a market opportunity of up to $2 billion for the drug, suggesting a premium pricing strategy.
For context, in 2016, the sales of Linzess (linaclotide) were $959 million, and those of Amitiza (lubiprostone) were $467 million.
For API buyers and generic manufacturers, the key cost drivers will include:
Patent Status: The basic patent for Plecanatide was noted to expire on March 28, 2022. This expiration opens the door for generic versions, which will dramatically reduce the cost of the API and finished formulations.
Scale of Purchase: Bulk purchasing of the API will offer substantial cost advantages per gram/kg.
Supplier and Purity: Costs will vary depending on the supplier (innovator vs. generic API manufacturers) and the required purity level.
Is Plecanatide a Stimulant Laxative?
No, Plecanatide is not a stimulant laxative.
This is a crucial differentiator. It belongs to a novel class of drugs known as guanylate cyclase-C (GC-C) agonists or prosecretory agents.
Stimulant Laxatives (e.g., bisacodyl, senna) work by directly irritating the colonic mucosa or stimulating the colonic nerves, prompting forceful bowel contractions. Long-term use can potentially lead to dependency and damage to the enteric nerves.
Plecanatide works by a completely different, hormone-mimicking mechanism that gently increases fluid secretion in the small intestine, leading to softer stools and more natural bowel movements without directly stimulating nerves. It is not associated with the “lazy bowel” syndrome or dependency risks of stimulant laxatives.
Is Plecanatide Sold in the EU?
The search results do not provide a specific date for its approval in the European Union.
The initial approval was in the United States in January 2017.
For the most current information on its status in the EU, Canada, Japan, and other major markets, it is essential to consult directly with the European Medicines Agency (EMA) or other relevant national regulatory bodies.
API suppliers should track the patent and regulatory status in target markets to identify opportunities for entry.
Is Plecanatide the Same as Linzess?
No, Plecanatide (Trulance) is not the same as linaclotide (Linzess).
While they are in the same drug class (GC-C agonists) and share a similar mechanism of action and indications, they are distinct molecular entities with differences in structure, origin, and clinical profile, as detailed in the comparison table above.
They are not interchangeable, at least without a physician’s supervision.
Is Plecanatide Safe During Pregnancy?
There is insufficient data from human studies to determine the safety of Plecanatide during pregnancy.
Because its systemic absorption is negligible, the theoretical risk to the fetus is considered low.
However, as a standard precaution for most pharmaceuticals, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Prescribing information typically classifies it as “Category C” or its equivalent, indicating that animal reproduction studies have not been conducted, or that risk cannot be ruled out.
A healthcare provider must make the final decision based on the individual patient’s needs.
Plecanatide Emerging Applications
Beyond its approved uses for CIC and IBS-C, preclinical research suggests Plecanatide has potential in other gastrointestinal disorders due to its anti-inflammatory properties.
Gastrointestinal Inflammation and Colitis: Animal studies have shown that Plecanatide can suppress inflammation in murine colitis models. It reduced abdominal contractions in a rat model of visceral hypersensitivity, suggesting a potential role in pain management.
Colorectal Cancer Prevention: Notably, one study found that Plecanatide suppressed inflammation-induced colorectal carcinogenesis in a genetically susceptible mouse model (Apc+/Min-FCCC mice). It reduced the proliferation of neoplastic colon epithelial cells. This suggests its potential chemopreventive role, although it is highly preliminary and far from clinical approvals.
These emerging applications, while not yet approved, highlight the potential of GC-C receptor activation and could represent future market expansions for Plecanatide.
Cost-Effective Bulk Purchasing Strategies for Plecanatide API Importers
For importers and generic manufacturers, strategic purchasing is key to profitability.
Monitor Patent Expirations: The primary opportunity arises after patent expiry. The basic patent was noted to expire in 2022. Track supplementary protection certificates (SPCs) that may extend market exclusivity in specific regions, such as Europe.
Diversify Supplier Base: Once the patent expires, avoid reliance on a single API manufacturer. Qualify multiple suppliers from different regions (e.g., China, India, Europe) to create competitive pricing and ensure supply chain resilience. Several Chinese companies (e.g., Zhejiang Peptide Biochemical, Hangzhou Sino-Spectra) were already listed as potential suppliers in pre-expiry data.
Volume Tiering: Negotiate pricing based on volume tiers. Purchasing in multi-kilogram quantities will offer the best cost per unit.
Long-Term Supply Agreements: Secure long-term supply agreements with qualified manufacturers to lock in prices and ensure API availability, particularly during the initial high-demand period following patent expiration
Invest in Quality: The lowest-priced API may not be the most cost-effective if it fails quality control tests, causes production delays, or leads to product recalls. Investing in a high-quality API from a reputable supplier is ultimately more cost-effective.
Compounding Pharmacy Guidelines for Plecanatide Formulations
While the commercial product (Trulance) is a solid oral tablet, compounding pharmacies may have alternative formulations for specific patient needs (e.g., liquid suspensions for patients with swallowing difficulties). Extreme caution is advised.
Legal and Regulatory Constraints: Compounding a drug that is commercially available is highly regulated. In many jurisdictions, it is only allowed if there is a documented patient need that the commercial product cannot meet (e.g., an allergy to an excipient or a need for a different dosage strength). Compounding Plecanatide API is subject to strict regulations regarding API sourcing and quality certification.
Stability Challenges: Peptides are genetically unstable. They are susceptible to degradation by oxidation, hydrolysis, and microbial growth. Formulating a stable liquid suspension is technically challenging and requires validated methods to test potency and sterility throughout the intended shelf life.
Dosing Accuracy: The therapeutic dose is 3 mg. Achieving a homogeneous distribution of such a small quantity of API in liquid form requires expertise and rigorous testing to ensure each dose is accurate.
Consultation is Key: Compounding pharmacies must work closely with clinical pharmacists, physicians, and regulatory experts before attempting to compound Plecanatide. Patient safety is the top concern.
Global Sourcing Tips for Plecanatide API
Sourcing a peptide API, such as Plecanatide, requires careful attention to quality and regulatory compliance.
Here are critical tips for importers:
Verify Regulatory Status: Confirm the legal status of Plecanatide API in your country. Is it approved for commercial use? Is the patent still valid? Sourcing a generic API before patent expiry carries significant legal risk.
Supplier Qualification: Prioritize suppliers with a proven track record in peptide synthesis. Look for manufacturers that comply with GMP and can provide relevant documentation, such as a Drug Master File (DMF).
Specify the Salt Form: Clearly specify whether you require Plecanatide or Plecanatide acetate (the acetate salt is commonly used for stability and solubility). Confirm the CAS numbers (467426-54-6 for the base; 1075732-84-1 for the acetate salt).
Quality Control (QC) and Analysis: Insist on comprehensive QC testing. The Certificate of Analysis (CoA) should include data on:
Purity (using HPLC).
Amino Acid Identity and Sequence (using Mass Spectrometry).
Correct Disulfide Bond Formation (critical for biological activity).
Water Content (for peptide stability).
Residual Solvents.
Logistics and Storage: Peptides are sensitive to heat and humidity. Ensure the supplier uses appropriate packaging and that your logistics chain can maintain the recommended storage conditions (typically -20°C for long-term storage).
Conclusion: Strategic Considerations for Plecanatide API Stakeholders
Plecanatide (Trulance) represents a milestone in the treatment of chronic gastrointestinal conditions, such as CIC and IBS-C.
Its novel, physiology-based mechanism of action, favorable efficacy profile, and minimal systemic absorption make it an attractive therapeutic option.
For API importers, manufacturers, and compounding pharmacies, the impending patent expiry of Plecanatide presents a substantial opportunity.
While its successful marketing will depend on a deep understanding of the molecule’s technical attributes—from its peptide structure and stability requirements to its distinct clinical advantages over competitors such as linaclotide.
By adhering to stringent quality control and implementing innovative sourcing strategies, you can effectively position your businesses to meet the growing demand for Plecanatide.
The future of Plecanatide may extend beyond constipation into new therapeutic areas; all we need to do is wait and see how the future plays out.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
